Merck's Keytruda Marches On In Melanoma With NICE Nod
This article was originally published in Scrip
Executive Summary
Merck & Co. Inc.'s PD-1 inhibitor Keytruda (pembrolizumab) has been given the provisional green light from the British national health technology association NICE as a treatment for some patients with advanced melanoma which is either inoperable or metastatic – provided the US drug maker makes the immune-oncology therapy available at an agreed discounted price.